Compare AMH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMH | CYTK |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | 1598 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.4B |
| IPO Year | N/A | 2004 |
| Metric | AMH | CYTK |
|---|---|---|
| Price | $33.23 | $71.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 19 | 19 |
| Target Price | $34.92 | ★ $89.26 |
| AVG Volume (30 Days) | ★ 3.1M | 2.2M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | $2.69 | $7.37 |
| Revenue Next Year | $2.26 | $310.19 |
| P/E Ratio | $26.59 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $27.22 | $31.99 |
| 52 Week High | $37.10 | $80.20 |
| Indicator | AMH | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 69.12 | 44.93 |
| Support Level | $32.05 | $59.07 |
| Resistance Level | $33.49 | $79.66 |
| Average True Range (ATR) | 0.60 | 2.49 |
| MACD | 0.05 | -1.11 |
| Stochastic Oscillator | 95.53 | 8.04 |
American Homes 4 Rent is a real estate investment trust focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's geographical markets include Dallas, Texas; Indianapolis, Indiana; Atlanta, Georgia; and Charlotte, North Carolina in terms of the number of properties in each.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.